1.Gennari, A., et al., Survival of metastatic breast carcinoma patients over a 20-year period. Cancer, 2005. 104(8): p. 1742–1750.
2.Chia, S. K., C. H. Speers, and D. Y. Y, The Impact of New Chemotherapeutic and Hormone Agents on Survival in a Population-based Cohort of Women with Metastatic Breast Cancer. Cancer, 2007. 19(2): p. 180–180.
3.Dafni, U., et al., Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Research and Treatment, 2010. 119(3): p. 621–631.
4.AG, W. and W. EP, Breast Cancer Treatment: A Review. JAMA, 2019. 321(3): p. 288–300.
5.Greenberg, P. A., et al., Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. Journal of Clinical Oncology, 1996. 14(8): p. 2197–2205.
6.Kiely, B. E., et al., How Long Have I Got? Estimating Typical, Best-Case, and Worst-Case Scenarios for Patients Starting First-Line Chemotherapy for Metastatic Breast Cancer: A Systematic Review of Recent Randomized Trials. Journal of Clinical Oncology, 2011. 29(4): p. 456–463.
7.Beslija, S., et al., Consensus on Medical Treatment of Metastatic Breast Cancer. Breast Cancer Research and Treatment, 2003. 81(S1): p. 1–7.
8.Pagani, O., et al., International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured? JNCI Journal of the National Cancer Institute, 2010. 102(7): p. 456–463.
9.Wahba, H. A. and H. A. El-Hadaad, Current approaches in treatment of triple-negative breast cancer. Cancer biology & medicine, 2015. 12(2): p. 106–16.
10.den Brok, W. D., et al., Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. Breast Cancer Research and Treatment, 2017. 161(3): p. 549–556.
11.Dent, R., et al., Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. Clinical Cancer Research, 2007. 13(15): p. 4429–4434.
12.Anders, C. K., et al., The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics. American Society of Clinical Oncology Educational Book, 2016. 36: p. 34–42.
13.Wang, X., et al., Immunological therapy: A novel thriving area for triple-negative breast cancer treatment. Cancer Letters, 2019. 442: p. 409–428.
14.Higgins, J. P. T., et al., The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. p. 889–893.
15.Nanda, R., et al., Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE–012 Study. Journal of Clinical Oncology, 2016. 34(21): p. 2460–2467.
16.Dirix, L. Y., et al., Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Research and Treatment, 2018. 167(3): p. 671–686.
17.Rugo, H. S., et al., Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer. Clinical Cancer Research, 2018. 24(12): p. 2804–2811.
18.S, A., et al., Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE–086 study. Annals of oncology: official journal of the European Society for Medical Oncology, 2019. 30(3): p. 397–404.
19.Adams, S., et al., Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE–086 study. Annals of Oncology, 2019. 30(3): p. 397–404.
20.Emens, L. A., et al., Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer. JAMA Oncology, 2019. 5(1): p. 74–74.
21.AC, S. Breast cancer survival rates. https://www.cancer.org 2017 [cited 2018 28 March].
22.Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine, 2019. 380(10): p. 985–988.
23.Cyprian, F. S., et al., Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer. Bosnian Journal of Basic Medical Sciences, 2019.
24.Tolaney, S., et al., Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer. European Journal of Cancer, 2017. 72: p. S16-S16.
25.Esteva, F. J., et al., Immunotherapy and targeted therapy combinations in metastatic breast cancer. The Lancet. Oncology, 2019. 20(3): p. e175-e186.
26.Santoni, M., et al., Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD–1/PD-L1 agents. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2018. 1869(1): p. 78–84.
27.Yin, T., et al., Aurora-A inhibition eliminates myeloid cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in breast cancer. Cancer Research, 2019: p. canres.3397.2018-canres.3397.2018.
28.Wang, Y., et al., 1160PMeta-Analysis of Anti-PD–1/PD-L1 Therapy Related Adverse Events in Clinical Trials. Annals of Oncology, 2017. 28(suppl_5).
29.Puzanov, I., et al., Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. Journal for ImmunoTherapy of Cancer, 2017. 5(1): p. 95–95.
30.Brahmer, J. R., C. Lacchetti, and J. A. Thompson, Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. Journal of Oncology Practice, 2018. 14(4): p. 247–249.